Why tocilizumab could be an effective treatment for severe COVID-19?

Fu B, Xu X, Wei H. · 2020

Read Why tocilizumab could be an effective treatment for severe COVID-19? by Fu B, Xu X, Wei H. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7154566.txt.

Description

Fu, Xu, and Wei argue that tocilizumab, a drug that blocks the interleukin-6 pathway, could treat severe COVID-19, in the Journal of Translational Medicine. About 25% of patients developed severe complications such as acute respiratory distress syndrome. Autopsy samples suggested a runaway immune response and cytokine storm clog the air sacs and drive the high death rate.

Their earlier work found pathogenic T cells and inflammatory monocytes pouring out interleukin-6 in severe cases. Blocking its receptor with tocilizumab gave encouraging early clinical results: fevers settled quickly and breathing improved. The authors present the drug as a way to calm the inflammatory storm and cut deaths in the sickest patients.

Catalog record

CREATORFu B, Xu X, Wei H.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE15 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7154566

Browse the full library · About the Tower of Babel